Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Non-Current Assets (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Other Non-Current Assets data on record, last reported at $376000.0 in Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $376000.0; the TTM value through Dec 2025 reached $376000.0, changed 0.0%, while the annual FY2025 figure was $376000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets reached $376000.0 in Q4 2025 per VRCA's latest filing, roughly flat from $376000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $40.0 million in Q2 2022 and bottomed at $142000.0 in Q1 2022.
  • Average Other Non-Current Assets over 5 years is $2.4 million, with a median of $376000.0 recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: surged 13935.09% in 2022, then plummeted 98.91% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $295000.0 in 2021, then decreased by 6.44% to $276000.0 in 2022, then skyrocketed by 63.77% to $452000.0 in 2023, then decreased by 16.81% to $376000.0 in 2024, then changed by 0.0% to $376000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $376000.0 in Q4 2025, $376000.0 in Q3 2025, and $376000.0 in Q2 2025.